Section 4.2.3 of the PAAB Code states:
Reporting clinical trial results in relative or proportional terms may lead to misinterpretation of the true benefit and degree of a treatment effect. APS which present results using these methods of reporting, namely relative risk (RR) or relative risk reduction (RRR), must also include an indication of the absolute treatment effect. This can be presented as absolute risk reduction (ARR), number needed to treat (NNT) and/or the actual comparative clinical results or rates. The overall presentation should reflect the true magnitude of benefit and not magnify the clinical effect. Undue emphasis on treatment effects in relative terms, by means of graphic presentation or differences in type size, is not acceptable.
This guidance document clarifies the PAAB's interpretation of "undue emphasis" in order to support consistent application of code section 4.2.3 in drug adverting.
Basic factors when assessing emphasis:
Additional factors, including but not limited to colour, contrast and graphic components, will be considered when assessing emphasis.
Previously accepted material will be reassessed and revisions may be required.
The following examples are intended to help in the development of advertising materials that present claims in relative terms.
Notes:
Notes:
Note:
Note:
Note:
Note:
Never miss an update. Get the latest PAAB info delivered right to your email address.
In an effort to constantly serve our clients better, PAAB has unveiled a new electronic submission process(eFiles). Effective January 2, 2008 all submissions will have to be submitted via the eFiles system. Please have a Senior Official (Director level) send an email to the administration team at review@paab.ca with the contact information of the person(s) who will be designated as administrator(s) for your company. Click on eFiles, on the menu, then eFiles Tutorial for a tutorial on how eFiles works.
Please contact the admin team at PAAB if you need assistance with eFiles
The Accelerated Preclearance Pathway
Learn more and share your feedback by April 14
Click here to provide feedback